An independent two-stage DCF analysis by a frontier AI model.
Becton Dickinson (BD) is the quintessential 'sleep well at night' healthcare stock. Its economic moat is practically impenetrable, forged by decades of embedding its essential products—from syringes to complex diagnostic machines—into the daily, critical workflows of hospitals globally. The switching costs for a hospital to move away from BD's integrated systems are prohibitively high, virtually guaranteeing a steady stream of recurring revenue. This fundamental strength makes BD highly resilient to macroeconomic shocks.
However, this ironclad predictability comes at a cost. The market clearly recognizes BD's defensive characteristics and prices the stock accordingly. Our DCF model suggests that at current levels, the stock is trading at a premium to its intrinsic value. Investors buying at these prices are paying up for safety and a reliable, growing dividend, rather than acquiring the stock at a discount. While it remains a superb underlying business, the lack of a margin of safety suggests waiting for a broader market pullback before initiating a position.
A 5.5% growth rate reflects steady, reliable expansion. BD's core medical supplies business grows in line with overall healthcare utilization, while its higher-margin diagnostic and life sciences segments provide a modest lift to overall cash generation.
An 8.0% discount rate is utilized, reflecting the highly defensive, recession-resistant nature of BD's business model. Its products are non-discretionary necessities for hospitals, resulting in incredibly stable and predictable cash flows.
A 2.5% terminal growth rate assumes BD will continue to grow slightly above the long-term rate of inflation and general economic growth, driven by an aging global population and increasing long-term demand for healthcare services.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 1.5% | $157.06 | $128.50 | $108.73 | $94.23 | $83.15 |
| 2.0% | $176.69 | $141.35 | $117.79 | $100.96 | $88.34 |
| 2.5% | $201.93 | $157.06 | $128.50 | $108.73 | $94.23 |
| 3.0% | $235.58 | $176.69 | $141.35 | $117.79 | $100.96 |
| 3.5% | $282.70 | $201.93 | $157.06 | $128.50 | $108.73 |
■ Undervalued vs current price ■ Overvalued vs current price
A strong company does not always equal a cheap stock. The market widely acknowledges BD's dominant position and defensive qualities, meaning these positives are already 'priced in.' The DCF model indicates that the current stock price demands growth rates slightly higher than what the company typically delivers.
The lower discount rate reflects lower risk. Because BD sells essential medical supplies that hospitals must buy regardless of the economic climate, its cash flows are far less volatile than those of a consumer discretionary or technology company.
A significant, accretive acquisition that meaningfully boosts free cash flow could increase the intrinsic value. Conversely, any major regulatory setbacks or product recalls—though rare for BD—would negatively impact the valuation.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.